Public Employees Retirement System of Ohio Has $9.58 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Public Employees Retirement System of Ohio cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 5.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 117,557 shares of the medical equipment provider's stock after selling 7,142 shares during the quarter. Public Employees Retirement System of Ohio owned about 0.05% of Hologic worth $9,576,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of HOLX. Wolff Wiese Magana LLC bought a new position in Hologic during the third quarter worth about $25,000. Innealta Capital LLC bought a new stake in shares of Hologic in the 2nd quarter worth about $25,000. First Horizon Advisors Inc. lifted its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. Sunbelt Securities Inc. bought a new stake in Hologic during the second quarter worth about $37,000. Finally, Cromwell Holdings LLC boosted its holdings in shares of Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after acquiring an additional 416 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Stock Performance

NASDAQ HOLX traded down $1.44 on Friday, reaching $73.65. The stock had a trading volume of 2,553,424 shares, compared to its average volume of 1,626,827. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The company has a market cap of $16.71 billion, a P/E ratio of 22.55, a price-to-earnings-growth ratio of 2.38 and a beta of 0.96. The firm has a fifty day moving average of $79.45 and a two-hundred day moving average of $78.56. Hologic, Inc. has a 1-year low of $70.24 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business's revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.89 EPS. On average, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the company's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.75% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

HOLX has been the topic of several research analyst reports. Wolfe Research started coverage on shares of Hologic in a research note on Friday. They set a "peer perform" rating on the stock. Citigroup lowered shares of Hologic from a "buy" rating to a "neutral" rating and cut their price objective for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Royal Bank of Canada upped their price objective on Hologic from $86.00 to $89.00 and gave the company a "sector perform" rating in a report on Tuesday, November 5th. Leerink Partners decreased their price target on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Finally, JPMorgan Chase & Co. increased their target price on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Hologic has a consensus rating of "Moderate Buy" and an average target price of $89.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.